Four Doors, One Disease
ME/CFS has a pattern that has puzzled researchers and clinicians for decades. The same syndrome — post-exertional malaise, cognitive dysfunction, unrefreshing sleep, autonomic dysregulation, widespread pain — appears in patients with radically different onset stories: a viral infection from which someone never recovered, a period of extreme psychological stress, major surgery, vaccination. The triggers are biologically distinct. The resulting disease is clinically indistinguishable [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway].
This is not a coincidence that calls for hand-waving.
1 One pathway, many entry points
The causal framework developed in chapters 16 and 33 proposes a specific answer: there are multiple entry points, but they converge on a single final common pathway [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway].
The framework proposes a final common pathway: CNS energy failure combined with broken restoration machinery [Ch. 16 §CNS Energy Crisis]. Once a patient’s physiology reaches this state — by whichever route — the downstream consequences are hypothesised to be determined by the pathway itself, not by the entry door. The autonomic failure, immune dysregulation, metabolic suppression, and sleep disruption that define ME/CFS are all properties of the pathway, not signatures of any particular trigger [Ch. 16 §Downstream Consequences]. Diverse inputs, convergent output.
2 The doors
Post-viral onset accounts for approximately 70% of ME/CFS cases — a figure consistent with published epidemiological surveys, though estimates vary across cohorts. The mechanism here is not the infection itself but what the infection initiates: a cascade of immune activation, cytokine signalling, and — in susceptible individuals — the first steps toward epigenetic stabilisation of the sickness program [Ch. 16 §Trigger-Capable Mechanisms]. For some patients, persistent viral reservoirs (latent EBV, HHV-6 reactivation, residual SARS-CoV-2 antigen in tissue) may continue driving the process directly. For others, the infection has long since cleared but the cascade it initiated has become self-sustaining [Ch. 16 §Viral Reactivation and Immune Exhaustion].
Severe physiological or psychological stress activates the HPA axis, produces sustained cortisol and catecholamine signalling, and creates conditions of neuroinflammation and immune dysregulation that overlap substantially with the post-viral cascade. The entry mechanism is different; the destination is the same [Ch. 16 §Trigger-Capable Mechanisms].
Major surgery — anaesthesia, systemic inflammation, significant oxidative stress, disruption of the gut-brain axis — presents a different picture [Ch. 16 §Trigger-Capable Mechanisms]. In a pre-sensitised individual, one whose parameters are already close to the separatrix (the boundary between the healthy basin and the disease basin), this combination of insults may be sufficient to tip the system across it [Ch. 16 §Relationships Among Trigger-Capable Mechanisms].
Vaccination-triggered onset is the rarest entry point and the one requiring the most precision. Vaccination-triggered ME/CFS represents a small fraction of cases. The proposed mechanism is not the vaccine antigen per se but an immune activation response that, in rare susceptible individuals, fails to self-limit and initiates the same cascade as post-viral onset [Ch. 16 §Trigger-Capable Mechanisms]. The existence of this entry point does not support vaccine hesitancy — uncontrolled natural viral infection poses substantially higher risks overall for susceptible individuals than vaccination, though precise comparative rates of ME/CFS onset per event are not established — but it is a real clinical phenomenon that the framework must account for.
3 Early and late disease are not the same problem
The funnel hypothesis generates a specific prediction about disease staging [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway]. In early disease (within the first year), patients stratified by onset type should show different biomarker profiles: post-viral patients should show signatures of viral immune response [Ch. 16 §Viral Reactivation and Immune Exhaustion], post-stress patients should show HPA axis dysregulation [Ch. 16 §Trigger-Capable Mechanisms], post-surgical patients should show inflammatory profiles consistent with surgical trauma [Ch. 16 §Trigger-Capable Mechanisms]. The entry door is still legible in the biology.
After several years — the framework proposes 3–5 as a working estimate, though this timeframe has not been established empirically — those early signatures should converge. As the amplifiers take over — epigenetic consolidation [Ch. 16 §Epigenetic Consolidation], autoantibody persistence [Ch. 16 §GPCR Autoantibody Cascade], metabolic entrenchment [Ch. 16 §Metabolic Safe Mode Lock] — the disease is increasingly maintained by the pathway itself rather than the original trigger. The entry door becomes less relevant to the current disease state [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway].
A treatment inference follows from this prediction, though it remains to be confirmed in stratified trials [Ch. 16 §Treatment Implications of the Causal Hierarchy]. The framework expects that early-stage patients may respond preferentially to treatments targeting their specific entry mechanism; for a post-viral patient in year one, antiviral approaches or immune modulation targeted at the viral cascade may be relevant. For a late-stage patient, the framework predicts that window has largely closed and the treatment target has shifted from the door to the locks — the mechanisms now hypothesised to maintain the disease independently of how it started [Ch. 16 §Load-Bearing versus Secondary Locks].
4 What the convergence explains
The convergence on a final common pathway explains why ME/CFS has been so difficult to characterise in research.
Studies that mix patients by disease duration will show heterogeneous biomarkers — not because the disease is “all over the place,” but because early patients reflect their entry pathway while late patients reflect the shared destination [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway]. On this model, the apparent heterogeneity is partly an artefact of mixing two phases of the same disease — though other sources of heterogeneity (genuine biological variation, diagnostic breadth) may also contribute.
It also explains the treatment response heterogeneity in clinical trials. A drug targeting the post-viral immune cascade will show a response signal in early post-viral patients and little signal in others. Mixed trials dilute this signal to noise. This is not evidence the drug doesn’t work; it may be evidence the trial was not stratified correctly.
The funnel is both the reason ME/CFS is clinically coherent (one syndrome, many triggers) [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway] and a source of apparent incoherence in the research record (inconsistent biomarkers, inconsistent treatment responses). Staging and stratification are not methodological niceties; they are how the signal becomes visible at all [Ch. 16 §Research Implications].
5 Going in vs. coming out
There is a useful asymmetry in the funnel. Going in, the entry door matters: different mechanisms, different early biomarkers, different early treatment windows [Ch. 16 §Entry Points: Multiple Doors, One Final Common Pathway]. Coming out — recovering — the door matters less. You cannot usually exit the way you entered, because the disease is no longer being maintained by the entry mechanism alone — with the exception of patients with confirmed active viral persistence, for whom entry-mechanism treatment may remain relevant regardless of disease duration [Ch. 16 §Viral Reactivation and Immune Exhaustion]. The framework predicts that recovery otherwise requires addressing the final common pathway and the locks that sustain it, regardless of how the patient arrived — a prediction that awaits confirmation in recovery-focused clinical studies [Ch. 16 §Treatment Implications of the Causal Hierarchy].
This asymmetry is one of the more clinically consequential predictions of the framework.
Previous article in this series: Not All Mechanisms Are Equal (2026-04-06)
Next: Load-Bearing Walls vs. Interior Walls — why treating what hurts most may matter less for recovery than treating what produces no immediate relief